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TEXT 
 
General consideration 
The development and availability of a trans-catheter approach for treating severe aortic valve 
stenosis (TAVI) has warranted clinical trials and observational studies to evaluate the safety and short/long 
term outcomes of newly designed prostheses in order to compare them with surgical aortic valve replacement 
(SAVR), the gold-standard treatment [1, 2]. The new treatment has been initially reserved for patients with 
absolute contraindications to surgery.  Subsequently the evidence of safety of the new devices, as well as the 
maturation of experience with this technology, has led to the expansion of indications to higher-risk patients 
[3, 4]. Nonetheless, technology runs fast, and new prostheses are regularly launched on the market claiming 
better performances and wider indications and hence requiring new evidence [5]. The PARTNER group 
recently published a comparison between the latest-generation SAPIEN3 TAVI system (Edwards 
Lifesciences, Irvine, CA, USA) and SAVR in intermediate-risk patients, apparently demonstrating 
superiority of the TAVI and suggesting that TAVI might be the preferred treatment method in this risk-class 
of patients [6]. These favourable results of transcatheter approach in intermediate risk-patients could lead the 
decision-makers and the scientific community to consider TAVI as the new standard of care in a wider 
population of patients with severe aortic stenosis. The recent Food and Drug Administration (FDA) approval 
for expanded indications for SAPIEN 3 device based on their data somewhat supports this position[7].  
Nonetheless [6], assessment of the non-randomised methodology used in this comparison reveals 
challenges which should be addressed in order to elucidate the validity of the results. The study is 
observational, employing propensity scores (PS),  risk scores that can be used to match patients with a 
similar likelihood of receiving treatment [8-10], since non-random differences in baseline will lead to bias in 
comparisons between treatment conditions [10]. PS analysis can be used to create a “quasi-randomized” 
comparison, but the approach has well-known intrinsic limitations and pitfalls including the misspecification 
of the PS, effects of unknown biases and confounding by indication [10-14]. Hence, unlike properly 
randomised trials, the use of the PS does not assure the internal validity of the analyses, and decision-makers 
and the scientific communities need to be wary of making inference from their results [12]. The PS study by 
Thourani and Colleagues has a number of major design flaws, and its results have clear signs of bias [6].  
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The assumption of “ignorability” and the effects of propensity score misspecification. 
The first important step in PS analysis is the careful specification of the risk algorithm, as omission 
of important confounding factors (eg getting it wrong) will lead to biased estimation of treatment effect. The 
objective is that as a result of the PS conditioning of the relevant explanatory variables, the treatment will be 
independent of potential outcomes. This conditional independence assumption is called “ignorability”, 
“unconfoundedness”, “selection on observables” and crucially it is always held as an assumption, because it 
is not directly testable [15]. In order to assume that treatment assignment is “otherwise ignorable” [10-16], 
the very first step is the inclusion in the PS algorithm of all known and available confounding factors, as 
explanatory variables that meet the condition of affecting both treatment assignment and outcome confound 
the observed relationship between treatment and outcome [10, 16]. The propensity score is compromised 
when important variables influencing selection have not been collected or considered and misspecification of 
the propensity score by excluding known confounders has been demonstrated to lead to largely biased results 
[11]. 
The study by Thourani and Colleagues was designed to compare outcomes of an observational study 
on the latest-generation SAPIEN 3 TAVI System (Edwards Lifesciences, Irvine, CA, USA) with results of 
the surgical group of the PARTNER 2A trial [5, 6, 17]. The two groups were not homogeneous, as shown in 
baseline characteristics [6] Thourani and Colleagues planned propensity score stratification before analysing 
outcomes.  The use of PS stratification rather than precise matching is surprising as it is by design limited in 
the extent to which systematic differences between the comparator groups may be accounted for.  Indeed 
there were important differences between the comparator samples.  The comparative analysis of patients’ 
baseline characteristics and baseline variables included in the PS algorithm showed that the most 
significantly different characteristics between the two groups (left ventricular ejection fraction LVEF, p-
value <0.0001; STS score, p-value 0.0002; moderate or severe mitral regurgitation, p-value <0.0001) were 
omitted in the PS generation, together with other significant factors (frail condition and mean gradient). 
These different baseline characteristics are well-known predictors of early and late mortality [18-25] and 
hence, affecting both treatment assignment and outcomes, are major confounders that should be included in 
the PS. Their omission may violate the “ignorability” assumption and, consequently, may lead to bias.  
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Moreover, further potential confounders not collected in the study are the associated procedures, 
such as myocardial revascularization. They increase the risk of perioperative mortality and morbidity as 
widely demonstrated by STS score and EuroSCORE [18-28], and they could represent a major confounder to 
be included in the PS algorithm. Nonetheless, although patients with non-complex coronary disease requiring 
revascularization were included if a treatment plan for the coronary disease was agreed before enrolment [5, 
6, 17], no information on associated myocardial revascularization in the TAVI group has been reported [6, 
17].  Some information on the SAVR group can be derived from the published PARTNER 2A trial [5] where 
a total of 86 of 944 patients (9.1%) had concomitant procedures during surgery and 137 of 944 patients 
(14.5%) underwent associated coronary artery bypass grafting (CABG) [5]. Thus a proportion ranging 
between 14.5% and 23.6% had concomitant surgical procedures in the SAVR group of the PARTNER 2A 
trial, indicating an increased risk of mortality and morbidity and potentially a major confounder. The need 
for a deep analysis on associated procedures in the Thourani’s study is also strengthened by the significantly 
different proportion of myocardial revascularization in the PARTNER 2A trial (137/994, 14.5% in the 
SAVR; 39/994, 3.9% in the TAVI group; Chi-square p-value <0.0001) [5]. 
 
Confounding by indication and assessing the performance of the propensity score. 
 Confounding by indication is the situation where, although all known confounders have been 
balanced, allocation to treatment is not otherwise ignorable but instead subject to some latent (unrecognized 
or unmeasured) process associated with those who are treated. This confounding cannot be measured directly 
but only tangentially through its effects and hence the effort should be focused on performance analysis of 
PS [12].    
 The first useful precaution against unsafe inference from an observational study is to compare it with 
a known treatment effect and bridge from that point to consider further questions. A deeper step in diagnostic 
should be the evaluation of PS performance through testing the potential heterogeneity of the treatment effect 
across the range of the PS. A comparison between two well-balanced groups should lead to a homogeneous 
treatment effect across the range of the PS, while heterogeneous effects will raise concern. 
The treatment effect of the observational study by Thourani and Colleagues [6] can be compared to 
the PARTNER 2A randomized trial [5]. As shown in Figure 1, the relative risk of the main outcome (all-
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cause death or disabling stroke) significantly differs from the two studies (interaction p-value =0.0001), 
which militates against drawing strong conclusions in the observational study. Moreover, a deeper analysis 
of the treatment effect across the PS quintiles shows that the treatment effect is not homogeneous across 
classes, showing a decreasing pattern through strata (Figure 2). Only the treatment effect in the fifth quintile 
is similar to the PARTNER 2A trial effect. It can be hypothesized that in patients with low likelihood of 
TAVI (lower quintiles of PS) there is important information that the PS did not capture and so the match was 
made with inappropriately low risk individuals, leading to a not otherwise ignorable treatment assignment. 
[12]   
 
To adjust or not to adjust, this is another question. 
The concerns also increase in the second part of the study, the time-to-event analyses. The study is 
based on evidence that groups are different and biased estimated of treatment effects needs to be accounted 
for by balancing the covariates with PS methods [6]. Nonetheless, after employing PS stratification for 
comparing dichotomic outcomes, the Authors surprisingly did notundertake any type of adjustment in time-
to-event analysis and presented simple unadjusted Kaplan-Meier estimates and curves, making inference on 
their results [6]. This is counterintuitive and the curves are not interpretable, as they are simply a first-step 
evaluation before adjustment. Stating in results “important differences between TAVR and surgery for each 
endpoint are observed in the first several months” is inappropriate until results are confirmed by adjusted 
results. Making inference on unadjusted outcomes derived from biased groups should be avoided [10, 14].  
 
Is there an outcome missing? 
In the PARTNER 2 SAPIEN 3 observation study, clinical outcomes were reported as defined by 
Valve Academic Research Consortium (VARC)-2 definitions [6, 29]. The VARC-2 definitions recommend 
capturing the cause of death with a careful review and, among mortality causes to be reported, all valve-
related deaths are included. Valve-related mortality and morbidity represent the main outcomes to evaluate 
the safety and short/long-term follow-up after valvular treatment, as it is the most specific index of early-late 
performance. In a comparison between two treatment options for valvular disease considering two 
homogeneous groups, we might reasonably expect to observe a similar non-cardiovascular and cardiac non-
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valve-related mortality, while the treatment effect would be expressed in differences in valve-related 
mortality [30]. Nonetheless, in the PARTNER 2 SAPIEN 3 observation study only all-cause mortality, non-
cardiac and cardiac death were reported, with no information on valve-related mortality shown. Therefore as 
it is not possible to differentiate prostheses-related events from prostheses-unrelated deaths, such as these 
caused by non-embolic myocardial infarction, defined as cardiac but non-valve-related death [29,30]. In the 
Thourani’s study,  30-day non-cardiac mortality is higher in the surgical group as shown in the Appendix 
(0.1% and 1.1% in the TAVR and surgical group respectively, Chi-square p-value 0.0152) which suggests 
the presence of confounding by indication. 
 
Conclusions 
 
As shown, the study on the comparison between SAPIEN3 TAVR and surgical AVR [6] has 
demonstrated several major methodological concerns: 
 suboptimal methods in propensity score analysis with evident misspecification of the PS (no 
adjustment for the most significantly different covariates: LVEF, moderate-severe MR, associated 
procedures) 
 Use of PS quintiles rather than matching 
 inference on not-adjusted Kaplan-Meier curves, although the Authors correctly claimed for the need 
of balancing score for adjusting for confounding factors in order to have unbiased estimates of the 
treatment effect 
 evidence of poor fit 
 lack of data on valve-related death 
These methodological flaws invalidate direct comparison between treatments and cannot support 
Authors’ conclusions that TAVI with SAPIEN 3 in intermediate-risk is superior to surgery and might be the 
preferred treatment alternative to surgery.  
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Figures legend 
Figure 1. Treatment effect of TAVR vs Surgery on all-cause mortality and stroke in PARTNER 2A 
randomized trial and PARTNER 2A SAPIEN 3 observational study. 
Figure 2. Treatment effect of TAVR vs Surgery on composite outcome (death, stroke and moderate or severe 
aortic regurgitation at 1 year) across the quintiles of propensity score in the PARTNER 2A SAPIEN 3 
observational study. 
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